Achilles Therapeutics News

Achilles Therapeutics Analyst Ratings

BenzingaApr 5 06:31 ET

B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5

BenzingaDec 14, 2023 07:18 ET

Achilles Therapeutics Analyst Ratings

BenzingaDec 14, 2023 07:16 ET

Chardan Capital Reiterates Buy on Achilles Therapeutics, Maintains $11 Price Target

BenzingaAug 7, 2023 05:36 ET

Achilles Therapeutics Analyst Ratings

BenzingaAug 7, 2023 05:35 ET

Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $11

BenzingaMay 11, 2023 05:27 ET

Chardan Adjusts Price Target on Achilles Therapeutics to $12 From $17, Keeps Buy Rating

MT NewswiresMar 8, 2023 08:25 ET

Analysts Conflicted on These Healthcare Names: Achilles Therapeutics (ACHL), Cidara Therapeutics (CDTX) and Moleculin Biotech (MBRX)

TipRanksJan 15, 2023 04:05 ET

Achilles Therapeutics Analyst Ratings

Benzinga Analyst RatingsDec 7, 2022 06:08 ET

Piper Sandler Maintains Overweight on Achilles Therapeutics, Lowers Price Target to $8

Benzinga Real-time NewsDec 7, 2022 06:08 ET

Chardan Capital Keeps Their Buy Rating on Achilles Therapeutics (ACHL)

TipRanksNov 9, 2022 07:40 ET

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Achilles Therapeutics (ACHL)

TipRanksAug 10, 2022 05:00 ET

Piper Sandler Adjusts Price Target on Achilles Therapeutics to $10 From $17, Reiterates Overweight Rating

MT NewswiresMay 31, 2022 05:30 ET